USING OUR PD3D™ CELL CULTURE MODELS, WE OFFER THE CAPACITY TO SCREEN YOUR COMPOUNDS FOR MOLECULES THAT EFFECTIVELY INHIBIT CANCER SIGNALING PATHWAYS.
With its large panel of patient-derived three dimensional (PD3D™) cell cultures, cpo – cellular phenomics & oncology fills the gap between in vitro cell lines and in vivo physiology, improving your success in translating pre-clinical data into clinical relevant information.
Cancer tissues are complex structures characterized by a variable cellular composition and a highly dynamic cross-talk with the surrounding microenvironment.
In basic research as well as in pre-clinical drug screenings in vitro models of human cancer are currently very simplified and mainly based on 2 dimensional (2D) systems that strongly differ from the tumor in situ. In these models cell morphology, cell response to external stimuli as well as cell-cell interaction are strongly altered due to the fact that they lack the peculiar 3D structure of in vivo tissue.
These limitations are partially overcome by 3D models that more accurately mimic the structure and complexity of cancer tissue. Due to their peculiar characteristics, these models better represent the physiological tumor structure in terms of morphology, cell-environment crosstalk and exchange of soluble factors such as nutrients, oxygens, growth factors as well as CO2 and waste. Moreover, the conformation of 3D cancer models reflects the diffusion of chemicals inside the tumor in vivo, making this model a proper system for drug efficacy studies.
When your goal is to determine the efficacy of newly developed anti-cancer compounds, weather you prefer commercially available cell lines or primary tumor cells directly isolated from fresh tumor tissues, we offer a large panel of 3D organoids from different tumor entities (Link to list).
- Morphology closer to in situ tissues
- Cell-environment crosstalk
- Presence of gradients of soluble factors (nutrients, oxygens, growth factors as well as CO2 and waste)
- Diffusion of chemicals similar to in vivo tumor mass